Russell Investments Group Ltd. cut its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 45.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,614 shares of the medical research company’s stock after selling 46,902 shares during the quarter. Russell Investments Group Ltd. owned about 0.08% of PRA Health Sciences worth $5,471,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in shares of PRA Health Sciences by 0.9% during the 1st quarter. BlackRock Inc. now owns 6,211,391 shares of the medical research company’s stock valued at $685,054,000 after acquiring an additional 52,524 shares during the period. FMR LLC raised its holdings in shares of PRA Health Sciences by 11.3% during the 1st quarter. FMR LLC now owns 2,881,740 shares of the medical research company’s stock worth $317,827,000 after buying an additional 292,887 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of PRA Health Sciences by 10.7% during the 2nd quarter. Prudential Financial Inc. now owns 1,038,297 shares of the medical research company’s stock worth $102,946,000 after buying an additional 100,536 shares in the last quarter. Pendal Group Ltd raised its holdings in shares of PRA Health Sciences by 9.1% during the 2nd quarter. Pendal Group Ltd now owns 898,987 shares of the medical research company’s stock worth $78,178,000 after buying an additional 74,844 shares in the last quarter. Finally, Frontier Capital Management Co. LLC increased its holdings in PRA Health Sciences by 2.8% in the 1st quarter. Frontier Capital Management Co. LLC now owns 896,923 shares of the medical research company’s stock worth $98,922,000 after purchasing an additional 24,207 shares in the last quarter. Institutional investors and hedge funds own 99.64% of the company’s stock.

In related news, major shareholder Fund Holdings L.P. Kkr sold 6,666,684 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $97.41, for a total transaction of $649,401,688.44. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.95% of the stock is owned by corporate insiders.

Shares of NASDAQ PRAH traded up $2.86 during trading on Friday, reaching $104.71. The company had a trading volume of 9,679 shares, compared to its average volume of 661,180. The company’s fifty day moving average price is $98.41 and its 200-day moving average price is $98.59. PRA Health Sciences Inc has a 12 month low of $82.12 and a 12 month high of $121.98. The stock has a market cap of $6.62 billion, a P/E ratio of 26.61, a PEG ratio of 1.36 and a beta of 1.13. The company has a quick ratio of 0.99, a current ratio of 0.99 and a debt-to-equity ratio of 1.11.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.11. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The firm had revenue of $763.31 million for the quarter, compared to analyst estimates of $764.95 million. During the same quarter in the previous year, the company posted $1.00 EPS. The business’s revenue was up 5.6% on a year-over-year basis. As a group, equities analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.

A number of brokerages have issued reports on PRAH. Svb Leerink reaffirmed a “market perform” rating on shares of PRA Health Sciences in a report on Tuesday, July 2nd. Barclays upped their target price on PRA Health Sciences from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Leerink Swann began coverage on PRA Health Sciences in a report on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 target price for the company. BidaskClub raised PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. Finally, Jefferies Financial Group upped their target price on PRA Health Sciences from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. PRA Health Sciences has an average rating of “Hold” and an average target price of $115.00.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Liquidity

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.